期刊文献+

盐酸普拉格雷合成工艺的改进 被引量:3

Optimization of synthetic process of prasugrel hydrochloride
下载PDF
导出
摘要 目的改进盐酸普拉格雷的合成工艺,以便于放大生产,提高产品纯度。方法以邻氟苯乙酸和环丙烷甲酸甲酯为原料合成环丙基-2-氟苄基酮,再用NBS溴代得到α-环丙基羰基-2-氟苄基溴,在碱存在下,与2-氧代.2,4,5,6,7,7a-六氢噻吩并[3,2-c]吡啶盐酸盐发生亲核取代反应,再经乙酰化和成盐反应制得盐酸普拉格雷。结果优化后的合成工艺操作简便,成本低廉,可获得高纯度的盐酸普拉格雷。结论新工艺总产率达到48%,有利于工业生产。 Objective To improve the synthetic process of prasugrel hydrochloride in order to enlarge production and get high purity. Methods 2-fluorine phenylacetic acid was reacted with methyl eyclopropanccarboxylate, followed by bromination with NBS to afford α-cyclopropyl carbonyl-2-fluorobenzyl bromide. The latter was condensed with 2-oxo-2,4,5,6,7,7a-hexahydro-thieno [ 3,2-c ] pyridine hydrochloride,and then acetylated and solified to finally afford prasugrel hydrochloride. Results The cost of this optimized synthetic process of prasugrel hydrochloride was obviously low,with easy operation process and availability of high purity. Conclusion The overall yield of new process was 48% , which ensured a more appropriate process for industrial production.
出处 《药学实践杂志》 CAS 2013年第3期195-197,共3页 Journal of Pharmaceutical Practice
关键词 盐酸普拉格雷 抗血栓药 药物合成 Prasugrel hydrochloride antithrombotic drug drug synthesis
  • 相关文献

参考文献6

  • 1宋建虹,杜小莉.新型口服抗血小板活化和聚集药物——普拉格雷[J].中国药学杂志,2010,45(17):1357-1358. 被引量:4
  • 2Jakubowski JA, Winters K J, Naganuma H, et al. Prasugrel : a novel thienopyridine antiplatelet agent. A review of preclinical and clin- ical studies and the mechanistic basis for its distinct antiplatelet profile[ J]. Cardiovascular Drug Rev, 2007, 25 (4): 357.
  • 3Alain B, Daniel F,Jian-Pierre M ,et al. Derivatives of alpha(2-oxo- 2,4,5,6,7,7a-hexahy drothieno [ 3,2-c] -5-pyridyl) phenyl acetic acid,and their use as platelet and thrombotic aggregation inhibi- tiors [ P ]. US. 4740510,1988 04-26.
  • 4Hiroyuki K, Fumitoshi A, Atsuhiro S,et al. Tetra-hydrothienopyri- dine derivatives, furo and pyrrolo analogs thereof and their prepa- ration and uses for inhibiting blood platelet aggregation [ P ]. EP 0542411,1993-05-19.
  • 5吴雪松,岑均达,郭珩.制备普拉格雷的中间体及其制备方法[P].CN101245072A,2008.
  • 6程兴栋,童玲,杨玉雷,袁哲东.普拉格雷的合成工艺研究[J].中国新药杂志,2010,19(15):1314-1316. 被引量:6

二级参考文献10

  • 1JAKUBOWSKI JA, WINTERS KJ, NAGANUMA H, et al. Prasugrel:a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis forits distinct antiplatelet profile [ J ]. Cardiovascular Drug Rev, 2007,25 (4) : 357 - 374.
  • 2HIROYUKI K, FUMITOSHIA, ATSUHIRO S, et al. Tetrahydrothienopyridine derivatives,furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation: EP,0542411 [ P]. 1993 -05 - 19.
  • 3KIKUO A, HIROYUKI M, MASAHIKO K, et al. 2-silyloaytetrahydropiridine, salt thereof and process for producing the same: EP, 0785205A1 [ P]. 1997 -07 -23.
  • 4ASHOK K, KETAN DHANSUKHLAL V, SANJAY GOVIND B, et al. Industrial process for preparation of clopidogrel hydrogen sulphate : WO, 104663 [ P]. 2005 - 11 - 10.
  • 5ALAIN B, DANIEL F, JEAN-PIERRE M, et al. Derivatives of alpha- ( 2-oxo -2,4,5,6,7,7 a-hexabydrothieno [ 3,2-c ] -5 -pyridyl) phenyl acetic acid and their use as platelet and thrombotic aggregation inhibitiors : US ,4740510 [ P ]. 1988 - 04 - 26.
  • 6FARID N A, PAYNE C D, SMALL D S, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently [ J ]. Clin Pharmacol Ther, 2007, 81 (5):735-741.
  • 7FDA. Label approved on 07/10/2009 for EFFIENT,NDA no. 022307 [EB/OL]. http: //www. accessdata. fda. gov/drugsatfda-docs/labelZ 2009/022307s0001bl. pdf.
  • 8JAKUBOWSKI J A, PAYNE C D, WEERAKKODY G J, et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects[ J]. J Cardiovasc Pharmacol, 2007, 49 (3) : 167-173.
  • 9WALLENTIN L, VARENHORST C, JAMES S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibi- tion than clopidogrel due to more effcient generation of its active metabolite in aspirin-treated patients with coronary artery disease [J]. Eur Heart J, 2008, 29(1):21-30.
  • 10WIVIOTT S D, BRAUNWALD E, MCCABE C H, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[ J]. N Engl J Med, 2007, 357(20):2001-2015.

共引文献11

同被引文献28

  • 1Lambropoulos J, Bergholdt AB. Method development and validation for the HPLC potency assay of prasugrel tablets [ J ]. J Pharm Bi- omed Anal,2000,24(2) :251 -258.
  • 2R Kishore Reddy Seerapu, Venkateswara Rao A, Lavanya P, et al. Development of Validation RP - HPLC Method For The Estimation of Prasugrel HC1 in Pure and Pharmaceutical Formulat- ions[ J]. Journal of Pharmacy Research, 2011,4 ( 9 ) : 3105 - 3107.
  • 3Pan X H, Huang R, Zhang J S, et al. Efficient synthesis of prasugrel, a novel P2Y12 receptor inhibitor[J]. Tetrahe- dronLetters, 2012 , 53,5364-5366.
  • 4Ryan W E, Jason R Z, Zhu S L, et al. Simple catalytic mechanism for the direct coupling of ot-carbonyls with FuncTionalized Amines:A One Synthesis of Plavix [J]. 2013,135:16074-16077.
  • 5荆亚萍,申东升,熊维,邓爵安.新一代血小板抑制剂——普拉格雷[J].国际药学研究杂志,2008,35(5):373-376. 被引量:22
  • 6孙志国,侯建,邹强,王国平,张越.普拉格雷的合成[J].中国医药工业杂志,2009,40(4):244-246. 被引量:16
  • 7荆亚萍,申东升,邓爵安,廖伦辉.普拉格雷中间体的合成研究[J].广东药学院学报,2009,25(3):272-274. 被引量:3
  • 8马培奇.抗血小板新药普拉格雷[J].上海医药,2009,30(9):407-408. 被引量:6
  • 9齐永斌,赵立强,吕健.普拉格雷的合成工艺改进[J].内蒙古石油化工,2009,35(15):100-101. 被引量:2
  • 10程兴栋,童玲,杨玉雷,袁哲东.普拉格雷的合成工艺研究[J].中国新药杂志,2010,19(15):1314-1316. 被引量:6

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部